Harmony Biosciences shared its third-quarter results, showing $269 million in sales and expects over $1 billion this year.

Nov 4, 2026, 10:22 AM ETResultsRead the original at Benzinga

Good for HRMY

Harmony reported $269 million in WAKIX sales for Q3 and expects more than $1 billion this year. One legal case remains open and BP205 results are preliminary, but current product demand supports the company.

HRMY · Harmony Biosciences Holdings

AI read · Good for HRMY

The AI's read

Patient demand is still adding users, and WAKIX is expected to pass the company's yearly sales milestone. Harmony says the drug's strength helps fund its research. The new CEO is an internal leader, but one legal case remains open and BP205 results are early. Those risks do not outweigh the sales progress.

Get alerts for HRMY

Follow Harmony Biosciences Holdings (HRMY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for HRMY

Free on the App Store and Google Play, or on the web.